Comparison of gadolinium‐enhanced and ferumoxytol‐enhanced conventional and UTE‐MRA for the depiction of the pulmonary vasculature
- 22 June 2019
- journal article
- research article
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 82 (5) , 1660-1670
Abstract
Purpose To evaluate the feasibility of ferumoxytol (FE)‐enhanced UTE‐MRA for depiction of the pulmonary vascular and nonvascular structures. Methods Twenty healthy volunteers underwent contrast‐enhanced pulmonary MRA at 3 T during 2 visits, separated by at least 4 weeks. Visit 1: The MRA started with a conventional multiphase 3D T1‐weighted breath‐held spoiled gradient‐echo MRA before and after the injection of 0.1 mmol/kg gadobenate dimeglumine (GD). Subsequently, free‐breathing GD‐UTE‐MRA was acquired as a series of 3 flip angles (FAs) (6°, 12°, 18°) to optimize T1 weighting. Visit 2: After the injection of 4 mg/kg FE, MRA was performed during the steady state, starting with a conventional 3D T1‐weighted breath‐held spoiled gradient‐echo MRA and followed by free‐breathing FE‐UTE‐MRA, both at 4 different FAs (6°, 12°, 18°, 24°). The optimal FA for best T1 contrast was evaluated. Image quality at the optimal FA was compared between methods on a 4‐point ordinal scale, using multiphase GD conventional pulmonary MRA (cMRA) as standard of reference. Results Flip angle in the range of 18°‐24° resulted in best T1 contrast for FE cMRA and both UTE‐MRA techniques (p > .05). At optimized FA, image quality of the vasculature was good/excellent with both FE‐UTE‐MRA and GD cMRA (98% versus 97%; p = .51). Both UTE techniques provided superior depiction of nonvascular structures compared with either GD‐enhanced or FE‐enhanced cMRA (p < .001). However, GD‐UTE‐MRA showed the lowest image quality of the angiogram due to low image contrast. Conclusion Free‐breathing UTE‐MRA using FE is feasible for simultaneous assessment of the pulmonary vasculature and nonvascular structures. Patient studies should investigate the clinical utility of free‐breathing UTE‐MRA for assessment of pulmonary emboli.Keywords
Funding Information
- National Institutes of Health (T32CA009206, K24 DK102595)
This publication has 19 references indexed in Scilit:
- Clinical outcomes after magnetic resonance angiography (MRA) versus computed tomographic angiography (CTA) for pulmonary embolism evaluationEmergency Radiology, 2018
- Relaxivity of Ferumoxytol at 1.5 T and 3.0 TInvestigative Radiology, 2018
- Contrast enhanced pulmonary magnetic resonance angiography for pulmonary embolism: Building a successful programEuropean Journal of Radiology, 2016
- Safety and technique of ferumoxytol administration for MRIMagnetic Resonance in Medicine, 2016
- Pulmonary Embolism Detection with Three-dimensional Ultrashort Echo Time MR Imaging: Experimental Study in CaninesRadiology, 2016
- Emerging applications for ferumoxytol as a contrast agent in MRIJournal of Magnetic Resonance Imaging, 2014
- Effectiveness of MR angiography for the primary diagnosis of acute pulmonary embolism: Clinical outcomes at 3 months and 1 yearJournal of Magnetic Resonance Imaging, 2013
- FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney diseaseAmerican Journal of Hematology, 2010
- Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field StrengthsInvestigative Radiology, 2005
- First‐pass contrast‐enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)‐based blood pool agentJournal of Magnetic Resonance Imaging, 2004